BioWest reviewing strategic options

In addition to pursuing the development of its current product candidates, BioWest Therapeutics (TSX:BWE) is exploring licensing-in new pharmaceutical and other life science product opportunities that are appropriately risk managed. “The focus will be to identify opportunities that are lower risk (compared to pre-clinical research projects) and that may be more easily understood and evaluated,” [...]

Stellar signs Uracyst distributor in Spain

Stellar Pharmaceuticals (OTCBB: SLXCF) has signed a license agreement with Laboratorios Inibsa S.A. for the sale and distribution in Spain of one of its lead products, Uracyst, for the treatment of interstitial cystitis/painful bladder syndrome. Uracyst already has CE mark approval in Europe and Inibsa is expected to launch the drug in the fourth quarter [...]

IntelGenx arranging $2.5 million private placement

IntelGenx Technologies (TSX-V:IGX) has retained Bolder Investment Partners to complete a private placement in Canada to raise up to $2.5 million by issuing units priced at 40 cents apiece. Each unit will consist of one common share and one warrant that can be exercised to purchase an additional common share of the company for 50 [...]

Angiotech posts positive results in MultiStem trial

Angiotech Pharmaceuticals (TSX:ANP; NASDAQ:ANPI) and partner Athersys (NASDAQ:ATHX) have released positive results from the Phase 1 clinical trial of MultiStem, an allogeneic-cell-therapy product, administered to individuals following acute heart attack. The study results, which represent at least four months of post-treatment patient data, demonstrate that MultiStem was “well tolerated at all dose levels and also [...]

Cipher readying tramadol launch in first quarter 2011

Cipher Pharmaceuticals (TSX: DND) is “working diligently” to finalize a marketing partnership and is finalizing commercial manufacturing requirements for its extended-release tramadol drug, which was cleared by the FDA in the second quarter, as it prepares for a commercial launch expected in the first quarter of 2011. The company also disclosed in its second quarter [...]

Stellar gets Uracyst patents in China and U.S.

Stellar Pharmaceuticals (OTCBB: SLXCF) has been issued patents for Uracyst, one of its lead products for the treatment of interstitial cystitis/painful bladder syndrome, by both the Chinese Patent Office and the U.S. Patent and Trademark Office. The Chinese patent covers pharmaceutical compositions that comprise the greater and superior dosage size of chondroitin sulfate, and the [...]

Cynapsus licenses in Parkinson’s drug

Cynapsus Therapeutics (TSX-V:CTH) has signed a license option agreement for all intellectual property  related to Adagio Pharmaceuticals’ APL-130277, a reformulation of an approved Parkinson’s drug. Under the accord, Adagio is entitled to receive 750,000 common shares of Cynapsus based on a price of 10 cents a share. A 12-month exclusive option period allows Cannasat to [...]

Response Biomedical taps OrbiMed in expansion drive

Besides arranging an $8 million private placement with funds affiliated with OrbiMed Advisors LLC, Response Biomedical (TSX:RBM; OTCBB:RPBF) is also in line for “collaborative benefits” from the investment fund’s Asian arm as it ramps up its expansion in China. At its annual meeting in Vancouver today, shareholders of the medical devices company are expected to [...]

Microbix lands partner for livestock sexing

Microbix Biosystems (TSX:MBX) has signed partnership agreements that will accelerate the development and commercialization of its LumiSort technology, which enables livestock breeders to predetermine the sex of their herd prior to conception. The first agreement is between Microbix and one of the largest suppliers of livestock reproduction products and services in the world. The partner [...]

Warnex in group to develop new diagnostic test

Warnex (TSX:WNX), the Montreal Heart Institute and the Centre of Excellence in Personalized Medicine are collaborating to develop a new diagnostic test for early detection of cardiovascular and metabolic diseases to enable more personalized treatment of diseases such as atherosclerosis and diabetes. The test will be developed by Warnex in collaboration with Dr. Eric Thorin, [...]

Next Page »